2013
DOI: 10.1111/acel.12107
|View full text |Cite
|
Sign up to set email alerts
|

Reducing sphingolipid synthesis orchestrates global changes to extend yeast lifespan

Abstract: Summary Studies of aging and longevity are revealing how diseases that shorten life can be controlled to improve the quality of life and lifespan itself. Two strategies under intense study to accomplish these goals are rapamycin treatment and calorie restriction. New strategies are being discovered including one that uses low-dose myriocin treatment. Myriocin inhibits the first enzyme in sphingolipid synthesis in all eukaryotes and we showed recently that low-dose myriocin treatment increases yeast lifespan at… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

6
71
0
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 66 publications
(78 citation statements)
references
References 45 publications
6
71
0
1
Order By: Relevance
“…30 By contrast with csg2Δ cells in which Snf1 activity is impaired in conjunction with IPC accumulation, inhibiting sphingolipid synthesis (with myriocin) has been reported to induce Snf1 activity, resulting in upregulation of genes involved in oxidative phosphorylation. 12 ROS proliferation is a cellular phenotype shared by csg2Δ cells and human sphingolipidoses, diseases in which sphingolipids build-up abnormally. 15 Significantly, our work highlights mitochondria and associated metabolic pathways as targets of lipid toxicity.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…30 By contrast with csg2Δ cells in which Snf1 activity is impaired in conjunction with IPC accumulation, inhibiting sphingolipid synthesis (with myriocin) has been reported to induce Snf1 activity, resulting in upregulation of genes involved in oxidative phosphorylation. 12 ROS proliferation is a cellular phenotype shared by csg2Δ cells and human sphingolipidoses, diseases in which sphingolipids build-up abnormally. 15 Significantly, our work highlights mitochondria and associated metabolic pathways as targets of lipid toxicity.…”
Section: Discussionmentioning
confidence: 99%
“…11 Recent work shows that Snf1/AMPK, a key regulator of energy metabolism, responds to changes in sphingolipid homeostasis. 12,13 These pathways involved in regulating and responding to sphingolipids are evolutionarily conserved.…”
mentioning
confidence: 99%
“…It is known that a defect in sphingolipid synthesis, as mediated by pharmacological inhibition or down-regulating expression of serine palmitoyltransferase (the first enzyme in the sphingolipid synthesis pathway (86)), extends chronological life span in yeast (118). This process involves the down-regulation of the Pkh1/2-Sch9 signaling pathway (118), which in turn activates the Snf1/AMP kinase signaling pathway and down-regulates the protein kinase A and target of rapamycin complex 1 signaling pathways (119). Because PI, one of the major phospholipids that is elevated in the pah1⌬ mutant (35), is the direct precursor for the synthesis of inositolphosphoceramide and mannose (inositol-P) 2 -ceramide (85, 86), we considered the hypothesis that the reduced chronological life span in the pah1⌬ mutant might also be ascribed to an increase in membrane sphingolipids.…”
Section: Discussionmentioning
confidence: 99%
“…A comparison of the genetic determinants of lifespan extension in the worm induced by various cytotoxic agents prominently featured ceramide and its metabolism. This is not surprising, as it is known that sphingolipids impact virtually every signaling pathway in the yeast cell that is relevant for longevity (Huang, et al, 2013, Liu, et al, 2013). This includes the various pathways and cellular processes with which the retrograde response cross-talks.…”
Section: Retrograde Signaling Is a Response To Cytotoxic Stressmentioning
confidence: 94%